IFRX: SEC Form 424B5 filed by InflaRx N.V.
Stocks in this Quantisnow insightHealth Care
Historical context for IFRX
Across the 19 sessions after earlier IFRX headlines, the stock closed higher 12 times and lower 6 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IFRX | SPY |
|---|---|---|---|
| May 6, 2026 | InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Sharesand 1 other headline that session | +26.9% | +1.4% |
| May 4, 2026 | InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes | +1.4% | -0.4% |
| May 1, 2026 | InflaRx to Report First Quarter 2026 Results on May 7, 2026 | +1.4% | +0.3% |
| Apr 28, 2026 | InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | +3.7% | -0.5% |
| Apr 24, 2026 | Oppenheimer resumed coverage on InflaRx with a new price target | -5.1% | +0.8% |
| Apr 9, 2026 | InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor | +8.4% | +0.6% |
Keep researching IFRX
Quantisnow market dataNASDAQ
IFRX
InflaRx N.V.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for IFRX
Full IFRX profile on Quantisnow Follow IFRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time